A marginal rank-based inverse normal transformation approach to comparing multiple clinical trial endpoints

Xiaoyu Cai, Huiyun Li, Aiyi Liu*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    6 Citations (Scopus)

    Abstract

    The increase in incidence of obesity and chronic diseases and their health care costs have raised the importance of quality diet on the health policy agendas. The healthy eating index is an important measure for diet quality which consists of 12 components derived from ratios of dependent variables with distributions hard to specify, measurement errors and excessive zero observations difficult to model parametrically. Hypothesis testing involving data of such nature poses challenges because the widely used multiple comparison procedures such as Hotelling's T2 test and Bonferroni correction may suffer from substantial loss of efficiency. We propose a marginal rank-based inverse normal transformation approach to normalizing the marginal distribution of the data before employing a multivariate test procedure. Extensive simulation was conducted to demonstrate the ability of the proposed approach to adequately control the type I error rate as well as increase the power of the test, with data particularly from non-symmetric or heavy-tailed distributions. The methods are exemplified with data from a dietary intervention study for type I diabetic children. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.

    Original languageEnglish
    Pages (from-to)3259-3271
    Number of pages13
    JournalStatistics in Medicine
    Volume35
    Issue number19
    DOIs
    Publication statusPublished - 30 Aug 2016

    Keywords

    • clinical trials
    • multiple endpoints
    • power of test
    • rank-based transformation
    • ratio of dependent variables
    • type I error

    Fingerprint

    Dive into the research topics of 'A marginal rank-based inverse normal transformation approach to comparing multiple clinical trial endpoints'. Together they form a unique fingerprint.

    Cite this